구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adcetris (Brentuximab vedotin, Brentuximab vedotin (Adcetris)) Seagen / Takeda·Anaplastic Large Cell Lymphoma, AL… 51 trials |
|---|---|
Overview Program | Brentuximab vedotin (Adcetris) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Anaplastic Large Cell Lymphoma, ALK-Posi |
Overview Indication | Anaplastic Large Cell Lymphoma, ALK-Positive |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin-containing regimen versus standard chem |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Safety signal | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Selected reported efficacy | ORR 89.5% |
Clinical Reported ORR | 89.5% |
Clinical Reported PFS | 8.0 |
Clinical Reported OS | 10.8 |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02588651 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adcetris (Brentuximab vedotin, Brentuximab vedotin (Adcetris)) Seagen / Takeda·Anaplastic Large Cell Lymphoma, AL… 51 trials |
|---|---|
Overview Program | Brentuximab vedotin (Adcetris) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Anaplastic Large Cell Lymphoma, ALK-Posi |
Overview Indication | Anaplastic Large Cell Lymphoma, ALK-Positive |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin-containing regimen versus standard chem |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Safety signal | Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.. Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study … |
Clinical Selected reported efficacy | ORR 89.5% |
Clinical Reported ORR | 89.5% |
Clinical Reported PFS | 8.0 |
Clinical Reported OS | 10.8 |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02588651 |
추천 비교
추천 비교